Article
Neurosciences
E. Kip, L. Bentall, C. F. Underwood, S. M. Hughes, L. C. Parr-Brownlie
Summary: Parkinson's disease is a motor disorder caused by altered neural activity, and optogenetic stimulation of glutamatergic motor thalamus neurons has shown potential in alleviating limb immobility in a rat model of Parkinson's disease, suggesting it as an alternative treatment for Parkinson's disease.
Article
Biochemistry & Molecular Biology
Victor Silva da Fonseca, Valeria de Cassia Goncalves, Mario Augusto Izidoro, Antonio-Carlos Guimaraes de Almeida, Fernando Luiz Affonso Fonseca, Fulvio Alexandre Scorza, Josef Finsterer, Carla Alessandra Scorza
Summary: Parkinson's disease is an incurable neurodegenerative disease with an increasing global disability and mortality rate. Non-motor symptoms are the main cause of disability and decreased quality of life. This study used metabolomics to assess changes in cardiac metabolism in a PD model.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Neurosciences
Ying Lyu, Yiying Huang, Guiying Shi, Xuepei Lei, Keya Li, Ran Zhou, Lin Bai, Chuan Qin
Summary: This study revealed gene expression changes in the five brain regions following exposure to 6-hydroxydopamine in PD rats, identifying key pathways and cascade involved in synaptic damage. The dopaminergic synapse, retrograde endocannabinoid signaling, and Gi/o-GIRK were highlighted as potential key pathways. Potential candidate genes such as Ephx2, Fam111a, and Gng2 were identified for further studies on the pathogenesis of PD.
CNS NEUROSCIENCE & THERAPEUTICS
(2021)
Article
Environmental Sciences
Camila G. Dantas, Ailma O. da Paixao, Tassia L. G. M. Nunes, Italo J. F. Silva, Bruno dos S. Lima, Adriano A. S. Araujo, Ricardo L. C. de Albuquerque-Junior, Katia P. Gramacho, Francine F. Padilha, Luiz P. da Costa, Patricia Severino, Juliana C. Cardoso, Eliana B. Souto, Margarete Z. Gomes
Summary: This study evaluated the neuroprotective effects of Africanized bee venom (BV) on a mice model of Parkinson's disease induced by 6-hydroxydopamine (6-OHDA). The results showed that BV could counteract the symptoms caused by 6-OHDA, reduce cell death, and protect the striatum from damage. These findings suggest that Africanized bee venom may have potential as a novel therapeutic approach for Parkinson's disease.
Article
Biochemistry & Molecular Biology
Hee-Yeong Kim, Hyung Ho Yoon, Hanyu Seong, Dong Kwang Seo, Soon Won Choi, Jaechul Ryu, Kyung-Sun Kang, Sang Ryong Jeon
Summary: We investigated the neuroprotective effects of deca nano-gra-phene oxide (daNGO) against reactive oxygen species (ROS) and inflammation in the human neuroblastoma cell line SH-SY5Y and in the 6-hydroxydopamine (6-OHDA) induced Parkinsonian rat model. daNGO showed neuroprotective effects against 6-OHDA-induced toxicity and also displayed ROS scavenging properties. The protective effects of daNGO were observed in the rat model, improving akinesia symptoms and decreasing net contralateral rotations.
Article
Biochemistry & Molecular Biology
Bira Arumndari Nurrahma, Tu-Hsueh Yeh, Rong-Hong Hsieh, Shu-Ping Tsao, Chia-Wen Chen, Yen-Peng Lee, Chun-Hsu Pan, Hui-Yu Huang
Summary: The study suggests that mangosteen pericarp extract may delay the progression of Parkinson's disease by counteracting oxidative stress and improving gut microbiota composition.
Article
Geriatrics & Gerontology
Jiewen Qiu, Guoyou Peng, Yuting Tang, Shiyin Li, Zengfu Liu, Jiayun Zheng, Yunxin Wang, Hanqun Liu, Lijian Wei, Yilin Su, Yuwan Lin, Wei Dai, Zhiling Zhang, Xiang Chen, Liuyan Ding, Wenyuan Guo, Xiaoqin Zhu, Pingyi Xu, Mingshu Mo
Summary: This study established a rat model of Parkinson's disease (PD) using 6-hydroxydopamine (6-OHDA) and analyzed the lipid profile in cerebrospinal fluid (CSF) using lipidomic approaches. The results showed significant effects of 6-OHDA on behavior, dopaminergic neurons, and lipid composition in CSF. Specific lipid families and species exhibited fluctuations during the progression of Parkinson's disease and were correlated with behavioral and pathological changes in the midbrain.
FRONTIERS IN AGING NEUROSCIENCE
(2023)
Article
Pharmacology & Pharmacy
Ana Carolina D. Noseda, Lais S. Rodrigues, Adriano D. S. Targa, Jessica L. Ilkiw, Juliane Fagotti, Patricia D. dos Santos, Erika Cecon, Regina P. Markus, Michele Solimena, Ralf Jockers, Marcelo M. S. Lima
Summary: Melatonin MT2 receptors in the glomerular layer are implicated in depressive-like behaviors and olfactory function impairment associated with Parkinson's disease, as demonstrated in a rat model using 6-OHDA-induced lesions. The activation of these receptors by melatonin and specific drugs shows potential for treating non-motor symptoms in PD.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Article
Immunology
Martina Mazzocchi, Susan R. Goulding, Noelia Morales-Prieto, Tara Foley, Louise M. Collins, Aideen M. Sullivan, Gerard W. O'Keeffe
Summary: The peripheral administration of Class IIa-specific HDIs may have neuroprotective effects in Parkinson's disease.
BRAIN BEHAVIOR AND IMMUNITY
(2022)
Article
Behavioral Sciences
Bita Firouzan, Farideh Iravanpour, Fatemeh Abbaszadeh, Valery Akparov, Jalal Zaringhalam, Rasoul Ghasemi, Nader Maghsoudi
Summary: This study investigated the effect of BHME on 6-OHDA-induced motor anomalies. Results showed that BHME prevented motor dysfunction and DA cell death following 6-OHDA injection, which was accompanied by an enhancement in Akt activity, decrement of P38 phosphorylation, and reduction in Bax/Bcl-2 ratio.
BEHAVIOURAL BRAIN RESEARCH
(2023)
Article
Pharmacology & Pharmacy
Li Zhou, Li-Fei Zheng, Xiao-Li Zhang, Zhi-Yong Wang, Yuan-Sheng Yao, Xiao-Lin Xiu, Chen-Zhe Liu, Yue Zhang, Xiao-Yan Feng, Jin-Xia Zhu
Summary: The study demonstrates that using α7nAChR agonists can alleviate inflammation and gastric dysmotility in PD rats by inhibiting NF-kappa B activation and monocyte chemotactic protein-1 expression.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Neurosciences
Luis Arturo Fonseca-Fonseca, Victor Diogenes Amaral da Silva, Maylin Wong-Guerra, Jeney Ramirez-Sanchez, Alejandro Saul Padron Yaquis, Estael Ochoa-Rodriguez, Yamila Verdecia-Reyes, Fillipe Mendes de Araujo, Rejane Conceica Santana, Tiago Fleming Outeiro, Silvia Lima Costa, Yanier Nunez-Figueredo
Summary: The novel compound JM-20 has shown neuroprotective effects against 6-OHDA-induced damage in both in vitro and in vivo models of Parkinson's disease. The mechanism of action involves controlling oxidative damage and mitochondrial dysfunction.
Article
Biochemical Research Methods
Feifei Zhu, Han Chen, Jinying Han, Weiwei Zhou, Qi Tang, Qian Yu, Shangshang Ma, Xiaoyong Liu, Shuhao Huo, Keping Chen
Summary: The study reports the development of a neurotoxin-induced silkworm model for Parkinson's disease and explores possible molecular mechanisms using proteomic and targeted metabolomic approaches. Results show that 6-OHDA treatment can induce PD-like symptoms in silkworms, indicating the potential of silkworm models in understanding the molecular and cellular mechanisms underlying PD.
JOURNAL OF PROTEOME RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Debora Masini, Carina Plewnia, Maelle Bertho, Nicolas Scalbert, Vittorio Caggiano, Gilberto Fisone
Summary: In Parkinson's disease, a wide range of symptoms affecting the peripheral and central nervous system appear before or simultaneously with the cardinal motor symptoms, requiring appropriate animal models for study. Injection of 6-OHDA in rodents can replicate several non-motor comorbidities associated with PD, but often leads to significant post-surgical mortality.
Article
Biochemistry & Molecular Biology
Okina Sakakibara, Mikako Shimoda, Gaku Yamamoto, Youichirou Higashi, Mayumi Ikeda-Imafuku, Yu Ishima, Masahiro Kawahara, Ken-ichiro Tanaka
Summary: Parkinson's disease (PD) is a neurodegenerative disorder characterized by loss of dopaminergic neurons and elevated inflammatory responses. The fusion protein Alb-Trx has shown effectiveness against respiratory and renal diseases. This study found that Alb-Trx inhibited neurotoxicity and oxidative stress in PD, improving intracellular signaling pathways and suppressing neuroinflammation. This suggests Alb-Trx may be a potential therapeutic agent for PD.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)